Stage 2 Trial of Pembrolizumab Plus Standard Chemotherapy for Gastric Cancers

Share this content:
Researchers are investigating the efficacy of pembrolizumab immunotherapy plus chemotherapy as perioperative treatment for patients with gastric cancer or adenocarcinoma of the gastroesophageal juncti
Researchers are investigating the efficacy of pembrolizumab immunotherapy plus chemotherapy as perioperative treatment for patients with gastric cancer or adenocarcinoma of the gastroesophageal juncti

Title: A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma1

Principal Investigators: Paul E Oberstein, MD, Columbia University

Description: For this open-label, phase 2 study, researchers are investigating the efficacy of pembrolizumab immunotherapy plus chemotherapy as perioperative treatment for patients with gastric cancer or adenocarcinoma of the gastroesophageal junction.

All patients will receive 3 cycles of an investigator's choice of standard chemotherapy regimen plus pembrolizumab before and after surgery, with 1 additional cycle of pembrolizumab prior to surgery. Patients will then receive 14 extra doses of pembrolizumab during 12 months of maintenance therapy post-surgery.

The primary outcome measure is 2-year disease-free survival. Secondary outcome measures are pathologic complete response rate and disease-free survival evaluated over 34 months, as well as overall survival and overall response rate evaluated over 5 years.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02918162.

Status: This study is open and recruiting patients as of October 25, 2017.

This study is sponsored by Columbia University.

Reference

  1. Clinicaltrials.gov. Perioperative chemo and pembrolizumab in gastric cancer. NCT02918162. https://clinicaltrials.gov/ct2/show/NCT02918162. Accessed October 25, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters